All In Biotech

Drug Trial Radar · NCT04455750

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

61

Actual

Start

Oct 14, 2021

Primary completion

Mar 15, 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant). Enzalutamide helps fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as rucaparib, fight prostate cancer by prevent tumor cells from repairing their DNA. Giving enzalutamide and rucaparib may make patients live longer or prevent their cancer from growing or spreading for a longer time, or both. It may also help doctors learn if a mutation in any of the homologous recombination DNA repair genes is helpful to decide which treatment is best for the patient.

Conditions

  • Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Adenocarcinoma
  • Stage IV Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • EnzalutamideDrug

    Given PO

  • Rucaparib camsylateDrug

    Given PO

  • PlaceboDrug

    Given PO

  • Leuprolide AcetateDrug

    Given IM

  • Goserelin AcetateDrug

    Given SC

  • DegarelixDrug

    Given SC

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic progression-free survival (rPFS)Time frame: Up to 5 years post treatment
  2. Overall survival (OS)Time frame: Up to 5 years post treatment

Locations

414 sites in 1 country. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Kaiser Permanente Dublin

    Dublin, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Kaiser Permanente Downtown Commons

    Sacramento, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Sharp Memorial Hospital

    San Diego, California

  • Kaiser Permanente-San Francisco

    San Francisco, California

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California

  • Kaiser Permanente San Leandro

    San Leandro, California

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California

  • Kaiser San Rafael-Gallinas

    San Rafael, California

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California

  • Kaiser Permanente-South San Francisco

    South San Francisco, California

  • Saint Helena Hospital

    St. Helena, California

  • Kaiser Permanente-Stockton

    Stockton, California

  • Northbay Cancer Center

    Vacaville, California

  • Kaiser Permanente Medical Center-Vacaville

    Vacaville, California

  • Kaiser Permanente-Vallejo

    Vallejo, California

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado

Showing 40 of 414 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.